MISC (OTC:MIHDF) Stock, Quote.Headers.trade-ideas

MISC Bhd is a maritime logistics company domiciled in Malaysia. The company organizes itself into five segments; Gas Assets & Solutions segment includes the provision of liquefied natural gas (LNG) carrier services and non-conventional gas asset solutions, Petroleum & Product Shipping segment includes the provision of petroleum tanker and chemical tanker services, Offshore Business segment owns, lease, operation, and maintenance of offshore, floating, production, and offloading terminals, Marine & Heavy Engineering segment include marine repair, marine conversion, and engineering and construction works, and Others segment includes integrated marine services, port & terminal services, maritime education & training, and other diversified businesses.

MISC Bhd

Jefferies analyst Chris LaFemina downgrades Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) from Buy to Hold and lowers the price target from $48 to $40.

News

Downgrades

Price Target

Analyst Ratings

Jefferies Downgrades Freeport-McMoRan to Hold, Lowers Price Target to $40

Goldman Sachs analyst Stephen Laszczyk maintains TKO Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>) with a Buy and raises the price target from $142 to $165.

Goldman Sachs Maintains Buy on TKO Group Holdings, Raises Price Target to $165

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.

Novo Nordisk Successfully Completes Phase 1b/2a Trial With Subcutaneous Amycretin In People Overweight Or With Obesity

Janney Montgomery Scott analyst Christopher Marinac initiates coverage on Trustmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMK#NASDAQ">TRMK</a>) with a Buy rating and announces Price Target of $42.

Initiation

TRMK

Janney Montgomery Scott Initiates Coverage On Trustmark with Buy Rating, Announces Price Target of $42

Financing

AFRM

The Wall Street Journal Reported Affirm Holdings To Get $750M In Funding From Liberty Mutual

Baird analyst William Power upgrades Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) from Neutral to Outperform and raises the price target from $115 to $160.

Upgrades

TWLO

Baird Upgrades Twilio to Outperform, Raises Price Target to $160

Canaccord Genuity analyst Michael Graham upgrades Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) from Hold to Buy and raises the price target from $5 to $10.

SGHC

Canaccord Genuity Upgrades Super Group (SGHC) to Buy, Raises Price Target to $10

EV <a href="https://www.benzinga.com/tech/24/11/42025190/nikola-recalls-72-of-its-trouble-ridden-bev-trucks-as-display-failure-raises-crash-risk">truck maker</a> Nikola Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKLA#NASDAQ">NKLA</a>) is reportedly exploring options including selling parts or all of the company to prevent a cash crunch.
What Happened: Nikola is also considering options including bringing on partners or raising new funds, according <a href="https://www.bloomberg.com/news/articles/2025-01-23/ev-maker-nikola-explores-sale-partnerships-with-cash-dwindling">to</a> a Bloomberg report, citing people familiar with the matter.
The report, however, noted that no decisions have been made. 
Nikola did not immediately respond to <a href="https://pro.benzinga.com/dashboard">Benzinga</a>&#8216;s request for comment.
However, during Nikola&#8217;s last earnings call in October, the <a href="https://www.benzinga.com/news/24/08/40310274/nikola-ceo-steve-girsky-is-not-worried-about-competition-from-tesla-battery-trucks-dont-work-everywh">company&#8217;s</a> CEO Steve Girsky admitted that the company is talking to potential partners who can provide capital.
&#8220;We are actively talking to lots of potential different partners who value what we do and value what we&#8217;ve built,&#8221;&nbsp;Girsky then said.
Why It Matters:&nbsp;The company in October also said that it has only sufficient capital to last through the first quarter of 2025. The company ended the third quarter with about $198 million in unrestricted cash
"We are examining every opportunity to optimize cash. We estimate that our existing cash is sufficient to fund our forecasted operating costs and meet our obligations into but not beyond Q1 2025. We continue to seek to maintain sufficient capital to support our business," company CFO&nbsp;Tom Okray&nbsp;then said.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43183608/tesla-launches-refreshed-model-y-variant-in-us-canada-after-china">Tesla Launches Refreshed Model Y In US With 25% Price Hike, Full Self-Driving Included</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

NKLA

Nikola Eyes Sale, New Partners As It Risks Running Out Of Cash By End Of First Quarter

Sam Altman-led OpenAI&nbsp;is reportedly engaged in intricate discussions to <a href="https://www.benzinga.com/news/24/09/41043358/sam-altman-poised-for-10-5b-payday-as-openai-transitions-to-for-profit-model-with-150b-valuation-on">transform into a for-profit entity</a>, but its board is grappling with valuing&nbsp;Microsoft Corp.'s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) stake while negotiating the worth of its new charitable division at $30 billion.
What Happened: The restructuring talks, ongoing since September, aim to split OpenAI into two entities. The charitable arm would retain&nbsp;a stake in the newly&nbsp;formed public benefit corporation (PBC).
Determining Microsoft&#8217;s equity in the PBC is a significant hurdle, as is deciding the equity for CEO Altman, according to a report <a href="https://www.ft.com/content/7dcd4095-717e-49f8-8d12-6c8673eb73d7">by</a> the Financial Times.
This comes at a time when President Donald Trump's administration announced the <a href="https://www.benzinga.com/general/market-summary/25/01/43184963/nvidia-microsoft-or-oracle-which-among-these-stargate-ai-project-beneficiaries-are-the-least-expensive-to-own">$500 billion Stargate AI project</a>, with OpenAI, Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), and SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) leading it.
According to the report, the charitable arm&#8217;s valuation could reach approximately $30 billion, with most of it realized as equity in the PBC. The rest would be in cash.
Also See:&nbsp;<a href="https://www.benzinga.com/25/01/43152627/microsoft-ceo-satya-nadella-stands-firm-after-elon-musk-questions-stargates-100-billion-funding-potential-all-i-know-is-im-good-for-my-80-billion" target="_blank" rel="noreferrer noopener">Satya Nadella Stands Firm After Elon Musk Questions Stargate's $100 Billion Funding Potential: ‘All I Know Is, I'm Good For My $80 Billion'</a>
The transition is crucial for OpenAI to secure additional funding for advanced AI development. However, it marks a departure from its non-profit roots, raising legal and ethical questions.
The company reportedly has a two-year deadline to finalize the conversion, or investors may reclaim part of their $6.6 billion investment.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: The transition of&nbsp;OpenAI&nbsp;to a for-profit structure has sparked significant legal and industry interest. The move is part of OpenAI&#8217;s strategy to evolve and align with its mission of ensuring artificial general intelligence (AGI) benefits humanity, as outlined in their&nbsp;<a href="https://www.benzinga.com/24/12/42712683/openai-lays-out-its-for-profit-transition-plans-says-it-must-evolve-to-advance-its-agi-mission">transition plans</a>&nbsp;announced in December.
However, this shift has not been without controversy.&nbsp;Elon Musk, one of the co-founders of OpenAI, has been actively opposing the change.
In early January, Musk&#8217;s legal team urged the attorneys-general of California and Delaware to <a href="https://www.benzinga.com/news/legal/25/01/42904926/elon-musk-pushes-california-delaware-attorneys-general-to-force-openai-stake-auction-amid-bitter-legal-battle-with-sam-altman">enforce an auction of OpenAI's stake</a>.
This legal battle has drawn attention from prominent figures like Geoffrey Hinton, known as the &#8220;Godfather of AI,&#8221; who has <a href="https://www.benzinga.com/general/education/25/01/42778778/elon-musk-gets-support-from-godfather-of-ai-geoffrey-hinton-in-battle-against-openai">sided with Musk in this dispute</a>.
The outcome of these discussions and legal challenges could significantly impact the future of AI development and the balance between profit and public benefit in the tech industry.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43153571/openais-sam-altman-flip-flops-on-trump-as-500-billion-stargate-ai-project-is-announced-years-after-praising-reid-hoffman-for-stopping-his-re-election">OpenAI&#8217;s Sam Altman Flip Flops On Trump After $500 Billion Stargate AI Project, Says &#8216;I Wish I Had Done More Of My Own Thinking&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

MSFT

ORCL

SFTBY

OpenAI Wrestles With Microsoft Stake Valuation As It Looks To Transition To For-Profit Entity Amid Trump's $500 Billion Stargate AI Project: Report

<a href="https://www.globenewswire.com/Tracker?data=ZuNgcYfS6Vg6ovJNaHcj_Zs842b7d-pN1VCwxTPk_IGkK8Shci9PsBs91FxFCM-tpQORAwmFo5i2ny2pDyHJFY0cm0LmvPQPnKY2Ii6sHx4=">Tevogen Bio Holdings Inc.</a> ("Company" or "Tevogen Bio") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T-cell therapeutics for infectious diseases and cancers, today announced key insights from its recent fireside chat during the J.P. Morgan Healthcare Conference. Utilizing artificial intelligence (AI) and machine learning (ML) has been critical for Tevogen Bio, given its core commitment to patient equity. By applying ML through Tevogen.AI, the company has already achieved notable cost and time efficiencies, developments that could translate directly into savings for patients. The discussion featured Dr. David Rhew, Global Chief Medical Officer &amp; VP of Healthcare at Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, who shared their vision for how AI is revolutionizing drug development and healthcare delivery.

Events

TVGN

Tevogen Bio On Thursday Reported On Its Recent Fireside Chat With Microsoft Discussing The  Future Of AI-Driven Drug Development During the J.P. Morgan Healthcare Conference

Earnings

BEDU

Bright Scholar Reported Q1 Revenue Of $56.8M, Adj EPADS Of $0.18

Shares of Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) rose sharply in today's pre-market trading after the company provided <a href="https://www.benzinga.com/news/earnings/25/01/43179578/twilio-stock-is-trading-higher-after-hours-whats-going-on">preliminary financial results for the fourth quarter.</a>
After the market close on Thursday, Twilio introduced new financial expectations in a regulatory filing. The company said it now expects fourth-quarter revenue growth of approximately 11% year-over-year, up from prior guidance of 7% to 8%.
Twilio shares jumped 18.5% to $134.40 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Allurion Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) gained 87.6% to $6.94 in pre-market trading after the company announced its intention to initiate a clinical study combining its Allurion program with GLP-1 agonists to improve muscle mass and overall body composition.</li>
<li>Starbox Group Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBX#NASDAQ">STBX</a>) gained 76.4% to $0.8999 in pre-market trading after dropping around 18% on Thursday. Starbox Group recently announced the launch of its StarboxAI-IntelliContentCreate platform.</li>
<li>Evaxion Biotech A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) rose 55% to $5.64 in pre-market trading after jumping 53% on Thursday. Evaxion recently said it completed dosing in phase 2 trial with personalized cancer vaccine EVX-01.</li>
<li>Dogwood Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) gained 44.6% to $19.30 in pre-market trading after jumping 377% on Thursday. Dogwood Therapeutics recently announced patient dosing for its Phase 2b trial evaluating halneuron will commence in the first quarter.</li>
<li>Aclarion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) rose 27.1% to $0.0549 in pre-market trading. Aclarion recently announced the pricing of $14.4m public offering of common stock and warrants.</li>
<li>Nvni Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) gained 25.5% to $1.87 in pre-market trading after the company announced it regained Nasdaq compliance regarding the minimum bid pricing list requirement.</li>
<li>BioXcel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) gained 21.5% to $0.4616 in pre-market trading after gaining over 4% on Thursday.</li>
<li>TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) gained 17.5% to $0.57 in pre-market trading after the company launched the LaunchBox monitor in Canada.</li>
<li>Septerna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) rose 14.2% to $20.99 in pre-market trading following a 5% decline on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Hyzon Motors Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYZN#NASDAQ">HYZN</a>) fell 46% to $0.4172 in pre-market trading. Hyzon Motors, last month, issued a worker adjustment and retraining notification and cited the inability to raise funding and uncertainty related to the availability of government subsidies.</li>
<li>Centessa Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTA#NASDAQ">CNTA</a>) shares fell 38.5% to $10.01 in pre-market trading.</li>
<li>Mineralys Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) fell 29.8% to $7.20 in pre-market trading.</li>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) shares tumbled 28.1% to $0.9999 in pre-market trading after jumping more than 5% on Thursday.</li>
<li>DallasNews Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DALN#NASDAQ">DALN</a>) shares fell 18.4% to $5.61 in pre-market trading after gaining over 3% on Thursday.</li>
<li>First Financial Bancorp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFBC#NASDAQ">FFBC</a>) dipped 13.8% to $24.11 in pre-market trading after the company reported fourth-quarter results.</li>
<li>Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) fell 13.4% to $0.0433 in pre-market trading. Conduit Pharmaceuticals shares dipped 20% on Thursday after the company board approved a 1-for-100 reverse stock split.</li>
<li>Valens Semiconductor Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLN#NYSE">VLN</a>) declined 12% to $2.58 in pre-market trading after declining 3% on Thursday.</li>
<li>Acacia Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTG#NASDAQ">ACTG</a>) fell 11.7% to $3.86 in today's pre-market trading.</li>
<li>PB Bankshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBBK#NASDAQ">PBBK</a>) shares dipped 10% to $13.59 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43158901/jim-cramer-says-this-tech-stock-is-speculative-but-he-likes-it">Jim Cramer Says This Tech Stock Is Speculative But He Likes It</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ACTG

ALUR

BTAI

CNTA

DALN

DWTX

EVAX

FFBC

HYZN

LITM

MLYS

NVNI

PBBK

SEPN

STBX

TRUG

Why Twilio Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket

KKR Extends FUJI SOFT Tender Offer Deadline To February 7 Amid Bain Capital's Potential Rival Bid

Macro Economic Events

Econ #s

Economics

U.K. Services Purchasing Managers Index Preliminary For January 51.2 Vs. 50.8 Est.; 51.1 (Revised) Prior

U.K. Manufacturing Purchasing Managers Index Preliminary For January 48.2 Vs. 46.9 Est.; 47.0 (Revised) Prior

U.K. Composite Purchasing Managers' Index Preliminary For January 50.9 Vs. 50.0 Est.; 50.4 Prior

Eurozone Services Purchasing Managers Index Preliminary For January 51.4 Vs. 51.4 Est.; 51.6 (Revised) Prior

HCOB Eurozone Composite Purchasing Managers Index Preliminary For January 50.2 Vs. 49.7 Est.; 49.6 Prior

Eurozone Manufacturing Purchasing Managers Index Preliminary For January 46.1 Vs. 45.6 Est.; 45.1 (Revised) Prior

Piper Sandler analyst Arvind Ramnani maintains Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) with a Overweight and raises the price target from $322 to $368.

Piper Sandler Maintains Overweight on Visa, Raises Price Target to $368

MISC

Comments

MISC

MISC (MIHDF) Forecast

MISC (OTC:MIHDF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga